Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDO Peptide Vaccine with Ipilimumab or Vemurafenib in Melanoma
NCT02077114Phase 1Completed
- Sponsor
- Herlev Hospital
- Start
- Feb 2014
- Primary completion
- Sep 2014
- Modality
- Prophylactic Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of io102 in Malignant Melanoma (MM) (2 arms), sponsored by Herlev Hospital. Primary endpoint: Number of Participants with Adverse Events at Day 84. Started Feb 2014; status: completed.
02
Drugs
io102
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02077114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077114.